From the publishers of JADPRO

Graft-vs.-Host Disease Resource Center

Advertisement

574 Addition of Ruxolitinb to Corticosteroids As First-Line Therapy for High-Risk Acute Graft Versus Host Disease in Allogeneic Peripheral Blood Stem Cell Transplantation

Last Updated: Monday, December 12, 2022

Results from a multicenter phase 2 study show that adding ruxolitinib to methylprednisolone could be an effective first-line therapy for newly diagnosed acute GVHD.

2022 ASH Annual Meeting
Advertisement
News & Literature Highlights
Advertisement
Advertisement